Telomere-targeted therapies in development
| Compound . | Mechanism . | Current study phase . | Indication(s) . |
|---|---|---|---|
| BIBR1532 | Small-molecule inhibitor of hTERT | Preclinical | Solid and hematologic malignancies |
| UV1 | hTERT peptide vaccine | Phase 2 | Melanoma and NSCLC |
| GX301 | hTERT peptide vaccine | Phase 2 | Prostate cancer |
| AST-1 | hTERT-directed dendritic cell | Phase 1 | AML and prostate cancer |
| VAC2 | hTERT-directed dendritic cell | Phase 2 | NSCLC |
| IME | Oligonucleotide complementary to hTERT template | Phase 3 | MDS and MF |
| Compound . | Mechanism . | Current study phase . | Indication(s) . |
|---|---|---|---|
| BIBR1532 | Small-molecule inhibitor of hTERT | Preclinical | Solid and hematologic malignancies |
| UV1 | hTERT peptide vaccine | Phase 2 | Melanoma and NSCLC |
| GX301 | hTERT peptide vaccine | Phase 2 | Prostate cancer |
| AST-1 | hTERT-directed dendritic cell | Phase 1 | AML and prostate cancer |
| VAC2 | hTERT-directed dendritic cell | Phase 2 | NSCLC |
| IME | Oligonucleotide complementary to hTERT template | Phase 3 | MDS and MF |